Natco Pharma submits application with USFDA for generic cancer drug
The company has submitted an Abbreviated New Drug Application (ANDA) containing a #39;paragraph IV#39; certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca#39;s Olaparib tablets in strengths of 100mg and 150mg.
The company has submitted an Abbreviated New Drug Application (ANDA) containing a #39;paragraph IV#39; certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca#39;s Olaparib tablets in strengths of 100mg and 150mg. The company has submitted an Abbreviated New Drug Application (ANDA) containing a #39;paragraph IV#39; certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca#39;s Olaparib tablets in strengths of 100mg and 150mg. Moneycontrol Latest News Read More
The company has submitted an Abbreviated New Drug Application (ANDA) containing a #39;paragraph IV#39; certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca#39;s Olaparib tablets in strengths of 100mg and 150mg.